Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar 27;7(3):315-26.
doi: 10.4254/wjh.v7.i3.315.

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Giulia Ganzetti  1 , Anna Campanati  1 , Annamaria Offidani  1
Affiliations
Review

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Giulia Ganzetti et al. World J Hepatol. .

Abstract

Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease (NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and end-stage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has been recently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases.

Keywords: Adipocytokines; Adipose tissue; Biologic therapies; Non-alcoholic fatty liver disease; Non-biologic therapies; Psoriasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comorbidities in psoriasis. NAFLD: Non-alcoholic fatty liver disease. IBD: Inflammatory bowel diseases.
Figure 2
Figure 2
Non-alcoholic fatty liver disease and the two hits hypothesis.
Figure 3
Figure 3
The vicious circle.
See this image and copyright information in PMC

References

    1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–271. - PubMed
    1. Ganzetti G, Campanati A, Scocco V, Brugia M, Tocchini M, Liberati G, Giuliodori K, Brisigotti V, Offidani A. The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol. 2014;94:715–717. - PubMed
    1. Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly. 2014;144:w13968. - PubMed
    1. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis. 2004;14:228–232. - PubMed
    1. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40 Suppl 1:S17–S29. - PubMed

LinkOut - more resources